doc. MUDr. Daniela Žáčková, Ph.D.
Associate professor, Department of Internal Medicine, Hematology and Oncology
Correspondence Address:
Jihlavská 340/20, 625 00 Brno
Phone: | +420 532 23 2838, 3603 |
---|---|
E‑mail: |
social and academic networks: |
---|
Total number of publications: 219
2010
-
Mechanismy rezistence k imatinibu: laboratorní a klinická rezistence
Year: 2010, type: Appeared in Conference without Proceedings
-
Minimal residual resistance in CML: Stable BCR-ABL gene expression at levels 0.01-0.1% (IS) in the consecutive samples may be associated with BCR-ABL mutation development and MMoR lost in a small number of tyrosine kinase inhibitor responders.
Year: 2010, type: Conference abstract
-
Nová doporučení ELN pro léčbu a monitorování CML
Year: 2010, type: Appeared in Conference without Proceedings
-
Persistent splenomegaly during imatinib therapy and the definition of complete hematological response in chronic myelogenous leukemia.
American Journal of Hematology, year: 2010, volume: 85, edition: 5
-
Sexualita u pacientů s chronickou myeloidní leukémií léčených imatinibem
Česká a slovenská psychiatrie, year: 2010, volume: 106, edition: 5
-
The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population
Year: 2010, type: Conference abstract
-
The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population
American Journal of Hematology, year: 2010, volume: 85, edition: 7, DOI
-
The Outcome of Unselected Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Treated with Imatinib In the First Line and the Prognostic Value of ELN Defined Responses-Population Based Analysis of 458 Patients Treated Between 2003-2009.
Year: 2010, type: Conference abstract
-
Visit of outpatient department, practical, guided work in groups with patients and their medial records
Year: 2010, type: Appeared in Conference without Proceedings
2009
-
Efficacy and Safety of Imatinib in the First Line Chronic Myeloid Leukemia (CML) Treatment. An Analysis of a Comprehensive Population-Based Database.
Year: 2009, type: Conference abstract